Search Results

Home → Flash News → New strategic partnership alert! 🚀 Dr.GPCR x Celtarys are teaming up to revolutionize fluorescent ligand development for GPCR research. Get custom, fast, and functional ligands backed by real scientists solving real assay problems. 🧪 “We don’t just deliver compounds. We solve assay problems.” – Dr. Maria Majellaro, CSO, Celtarys Listen to Ep. 168 now and meet your new assay partner 😉 ✳️ https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-168-with-dr.-maria-majellaro-from-celtarys #GPCRdrugDiscovery #FluorescentLigands #DrGPCR #BiotechTools #AssayDevelopment Published on June 10, 2025 Category Dr. GPCR Podcast New strategic partnership alert! 🚀 Dr.GPCR x Celtarys are teaming up to revolutionize fluorescent ligand development for GPCR research. Get custom, fast, and functional ligands backed by real scientists solving real assay problems. 🧪 “We don’t just deliver compounds. We solve assay problems.” – Dr. Maria Majellaro, CSO, Celtarys Listen to Ep. 168 now and meet your new assay partner 😉 ✳️ https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-168-with-dr.-maria-majellaro-from-celtarys #GPCRdrugDiscovery #FluorescentLigands #DrGPCR #BiotechTools #AssayDevelopment Previous Next Recent Articles

Home → Flash News → Think βCGRP is just αCGRP’s understudy? Think again. New research shows that βCGRP triggers distinct receptor signaling profiles across the CGRP receptor family, challenging the long-held assumption of redundancy. 🔬 A closer look reveals differences in G protein coupling, second messenger production, and receptor trafficking. 📊 This could reshape how we understand CGRP-related physiology—and how we target it in drug design. 🧠 Pain, inflammation, metabolism: the implications go far beyond signaling bias. 🔗 Read the full paper in Biochemistry: Unique Biased Agonism Profile of βCGRP on CGRP Family Receptors #GPCR #CGRP #DrugDiscovery #Pharmacology #SignalTransduction #Neuropeptides Published on June 16, 2025 Category GPCR Weekly News Think βCGRP is just αCGRP’s understudy? Think again. New research shows that βCGRP triggers distinct receptor signaling profiles across the CGRP receptor family, challenging the long-held assumption of redundancy. 🔬 A closer look reveals differences in G protein coupling, second messenger production, and receptor trafficking. 📊 This could reshape how we understand CGRP-related physiology—and how we target it in drug design. 🧠 Pain, inflammation, metabolism: the implications go far beyond signaling bias. 🔗 Read the full paper in Biochemistry : Unique Biased Agonism Profile of βCGRP on CGRP Family Receptors #GPCR #CGRP #DrugDiscovery #Pharmacology #SignalTransduction #Neuropeptides Previous Next Recent Articles

Home → Flash News → Did you know that A2B adenosine receptor-triggered calcium mobilization varies by cell type? A recent study explores how Gi, Gq, Gs proteins, and PKC contribute differently to intracellular Ca²⁺ signaling, revealing a more complex regulation than previously thought. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/a2b-adenosine-receptor-triggered-intracellular-calcium-mobilization%3A-cell-type-dependent-involvement-of-gi%2C-gq%2C-gs-proteins-and-protein-kinase-c #gpcr #drgpcr #metabolism #obesity Published on March 10, 2025 Category GPCR Weekly News Did you know that A2B adenosine receptor-triggered calcium mobilization varies by cell type ? A recent study explores how Gi, Gq, Gs proteins, and PKC contribute differently to intracellular Ca²⁺ signaling, revealing a more complex regulation than previously thought. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https:// www.ecosystem.drgpcr.com/receptor-activation-and-signaling/a2b-adenosine-receptor-triggered-intracellular-calcium-mobilization%3A-cell-type-dependent-involvement-of-gi%2C-gq%2C-gs-proteins-and-protein-kinase-c #gpcr #drgpcr #metabolism #obesity Previous Next Recent Articles

< Back This is a Title 03 This is placeholder text. To change this content, double-click on the element and click Change Content. This is placeholder text. To change this content, double-click on the element and click Change Content. Want to view and manage all your collections? Click on the Content Manager button in the Add panel on the left. Here, you can make changes to your content, add new fields, create dynamic pages and more. You can create as many collections as you need. Your collection is already set up for you with fields and content. Add your own, or import content from a CSV file. Add fields for any type of content you want to display, such as rich text, images, videos and more. You can also collect and store information from your site visitors using input elements like custom forms and fields. Be sure to click Sync after making changes in a collection, so visitors can see your newest content on your live site. Preview your site to check that all your elements are displaying content from the right collection fields. Previous Next News Get in Touch Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About

<< Back to podcast list Strategic Partner(s) Dr. Kathryn E Livingston About Dr. Kathryn E Livingston Dr. Kathryn E Livingston is currently a Product Manager at Gator Bio , a biotechnology company providing solutions to researchers studying protein-protein interactions. Kathryn obtained her BS in Chemistry from Carnegie Mellon University and went on to receive a Ph.D. in Pharmacology at the University of Michigan. Working under the supervision of Dr. John Traynor , Kathryn worked to develop and understand first-in-class allosteric modulators of opioid receptors. Research into their mechanism of action in purified systems formed the base of her thesis work. Following this, Kathryn did a post-doctoral fellowship at UCSF in the laboratory of Dr. Mark von Zastrow . There she researched the beta-2 adrenergic receptor and developed assays to investigate real-time activity in intact cellular systems. Kathryn’s passion is developing solutions to problems in whatever form is most efficient: novel instrumentation, novel methods, or novel communication. Dr. Kathryn E Livingston on the web LinkedIn ResearchGate Pubmed Google Scholar Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Kevin Pfleger About this episode Dr. Pfleger trained as a pharmacologist and obtained his Ph.D. at the University of Edinburgh. I sat down with Kevin to chat about GPCRs, pharmacology, and his contributions to the field in both the academic and biotech worlds. Professor Pfleger has developed extensive expertise in profiling receptor binding and function at the molecular and cellular levels over the last 20 years, particularly involving GPCRs. He also has globally-recognized expertise in bioluminescence resonance energy transfer (BRET) technology, including his patented Receptor-Heteromer Investigation Technology (Receptor-HIT) for studying heteromers. Kevin is also Director, Biomedical Innovation at The University of Western Australia (UWA) and the MTPConnect Western Australian Life Sciences Innovation Hub. He is Head of Molecular Endocrinology and Pharmacology at the UWA Centre for Medical Research and Harry Perkins Institute of Medical Research, Deputy Director of the Australian Research Council Centre for Personalised Therapeutics Technologies, Chief Scientific Advisor to Dimerix, and co-founder of RAGE Biotech . He currently serves on the Board of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists and is a member of the British Pharmacological Society International Advisory Group. Join me and learn more about Kevin’s work and how he manages all his responsibilities. Dr. Kevin Pfleger on the web LinkedIn ResearchGate Pubmed Google Scholar University of Western Australia Harry Perkins Institute of Medical Research Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Gregory Tall About Dr. Gregory Tall " Dr. Gregory Tall earned his Ph.D. in Biomedical Sciences from U.T. Southwestern Medical Center with Bruce Horazdovsky, Ph.D. They worked on the interactome of yeast and mammalian Rab5 homologs including identification of Rab5 GEFs. In 2000, Dr. Tall moved upstairs to conduct his postdoctoral work on heterotrimeric G proteins and the novel interactor, Ric-8 with Alfred Gilman, M.D. Ph.D. In 2007, Dr. Tall joined the faculty in the Department of Pharmacology and Physiology at the University of Rochester Medical Center, there establishing his lab and major research directions. Dr. Tall moved to the University of Michigan in 2016 as an Associate Professor of Pharmacology and is a current active member of the department. The current goals of the Tall lab are to understand the basic mechanism by which Ric-8 proteins fold all heterotrimeric G protein alpha subunits, to exploit a Ric-8-based technology to purify recombinant G proteins and to use the G proteins in assays to explore the mechanisms of action of the 33-member adhesion GPCR family or Family B2 GPCRs. We found that adhesion GPCRs are activated by a tethered peptide agonist mechanism that differed from the common example known at the time, protease activated receptors (PARs). PARs have an N-terminal leader sequence that is clipped by exogenous proteases to reveal a new N-terminus that serves as the tethered agonist. Adhesion GPCRs pre-cleave themselves and the two resultant fragments of the receptor remain together to conceal the tethered peptide agonist. Mechanical dissociation of the two fragments aided by protein binding ligands and cell movement serves to decrypt the tethered agonist for binding to its orthosteric site. Our current goals are to explore this mechanism in detail and to understand how it may happen for the 33 adhesion GPCRs in complex physiological contexts…one being our discovery that GPR56 is the platelet receptor that senses collagen and shear force to initiate the platelet activation program. Dr. Tall has been continuously funded by the NIH since receiving an early RO1 award at Rochester. He has continued funding at Michigan through the MIRA R35 program. Dr. Tall has presented his work at 59 invited seminars including national and international meetings and academic departmental seminars. " Dr. Gregory Tall on the web The Tall Lab University of Michigan Google Scholar Twitter Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

AI is transforming GPCR modeling. Jens Carlsson challenges scientists to go beyond explaining data — and start predicting the future of receptor function and drug discovery. Home → Flash News → ep 175 with jens carlsson clip 3 AI is changing how we think about structure, function, and discovery Published on November 4, 2025 Category Dr. GPCR Podcast AI is changing how we think about structure, function, and discovery — but Jens Carlsson reminds us: the real test isn’t whether we can explain today’s data, it’s whether we can predict tomorrow’s results . In this clip, Jens unpacks a mindset shift that every computational scientist should hear. For decades, molecular modeling focused on explaining — rationalizing why a ligand binds, why a mutation shifts signaling, why a simulation behaves a certain way. But explaining is retrospective. Prediction is transformative. With tools like AlphaFold , his lab can now model receptor–peptide complexes in seconds — an achievement that once took months. Yet Jens’s caution stands: prediction must be proven. A good model doesn’t just match published structures; it forecasts new biology, new ligands, and new function. That’s where the future of GPCR research lies — not in describing the past, but in anticipating it. Whether you’re running simulations, screening compounds, or designing next-gen molecules, this insight reframes what “success” in computational pharmacology really means. 👉 Watch the full episode: model predict discover #GPCR #DrGPCR Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) Dr. Ross Cheloha About this episode Dr. Ross Cheloha is an Investigator at the National Institutes of Health in the Laboratory of Bioorganic Chemistry in Bethesda, MD, where he started in October 2020. He completed his postdoctoral training at MIT and Harvard Med School in the lab of Hidde Ploegh , where he developed new applications of single-domain antibodies (nanobodies). He earned his Ph.D. in Chemistry at the University of Wisconsin-Madison in the lab of Sam Gellman on the study of analogs of the GPCR peptide ligand parathyroid hormone. Work in his independent laboratory is focused on developing new pharmacological tools via chemistry and protein engineering to interrogate GPCR signaling. Ross and I chatted about his work and transition to an independent investigator; join me to learn more about class B GPCRs and Dr. Cheloha’s work. Dr. Ross Cheloha on the web NIDDK Cheloha Lab Google Scholar LinkedIn Twitter ResearchGate Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda State of the Art Talk Adhesion GPCR in Mechanobiology Abstract Only Available for AGPCR24 Attendees About Tobias Langenhan "1997-2004: Medical school and Dr. med. Neuroanatomy (Würzburg, Germany); 2004-2005: M.Sc . Neuroscience (Oxford, UK); 2005-2009: D.Phil. Neuroscience (Oxford, UK); 2009-2016: Group leader, Institute of Neurophysiology (Würzburg, Germany); 2016: Heisenberg professorship (Würzburg, Germany); 2016-to date: Professor and Chair in Biochemistry (Leipzig, Germany)" Tobias Langenhan on the web Langenhan Lab LinkedIn < Previous Session Next Session >

<< Back to podcast list Strategic Partner(s) Dr. Bryan Roth About this episode Dr. Bryan Roth is the Michael Hooker Distinguished Professor of Pharmacology at the University of North Carolina Chapel Hill School of Medicine. After receiving his MD and Ph.D. in Biochemistry from St. Louis University in 1983, he subsequently trained in pharmacology (NIH), molecular biology, and psychiatry at Stanford. Bryan leads a $26.9 Million project to create better psychiatric medications, among other things. But, it wasn’t always this way. Bryan got fascinated with receptors after attending the lecture of a visiting professor on neurotransmission while in college in Montana, where he is from. He was determined to work on psychiatric disorders and persevered even when he was told several times he would never make it as a basic scientist and would never publish anything important. Join me and learn more about Bryan and his work. Dr. Bryan Roth on the web UNC School of Medicine / Pharmacology Roth Lab Roth Leads $26.9 Million Project to Create Better Psychiatric Medications LinkedIn Bryan Roth on Twitter Roth Lab on Twitter Google Scholar Pubmed Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Your complete guide to AGPCR24. Inside, you’ll find the schedule, speaker bios, venue map, travel tips, and essential information to make the most of your workshop experience. OFFICIAL BOOKLET Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF You can also download the booklet by scanning this QR code

The Practical Assessment of Signaling Bias Dr. Terry Kenakin Get Started Premium Members benefits: - Subscribe and save 25% on every GPCR Course - Early-bird access - Recordings will be available < Back to GPCR courses Watch recording Your Instructor Dr. Terry Kenakin

Home → Flash News → 💡 GPCR drug development doesn’t have to be a mystery! Learn from Dr. Terry Kenakin in this 4-week immersive course covering ligand development & pharmacology. 🔹 What you’ll learn: ✅ Drug Development Basics – Absorption, metabolism, PK principles ✅ Clearance & Distribution – Renal & hepatic clearance, key pharmacokinetics ✅ PK-PD Modeling – Predicting drug behavior, non-linear PK ✅ Early Drug Safety – Toxicity risks & drug interactions 📌 Spots are filling fast! Sign up today 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #Biotech #DrugDiscovery Published on March 8, 2025 Category Dr. GPCR Courses 💡 GPCR drug development doesn’t have to be a mystery! Learn from Dr. Terry Kenakin in this 4-week immersive course covering ligand development & pharmacology. 🔹 What you’ll learn: ✅ Drug Development Basics – Absorption, metabolism, PK principles✅ Clearance & Distribution – Renal & hepatic clearance, key pharmacokinetics✅ PK-PD Modeling – Predicting drug behavior, non-linear PK✅ Early Drug Safety – Toxicity risks & drug interactions 📌 Spots are filling fast! Sign up today 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #Biotech #DrugDiscovery Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) The Role of Quantitative Sciences in GPCRs with Dr. Nagarajan Vaidehi About Dr. Nagarajan Vaidehi "Nagarajan Vaidehi, Ph.D., is professor and chair of the Department of Computational and Quantitative Medicine (DCQM) at the Beckman Research Institute of the City of Hope in Los Angeles, CA. She is also the Associate Director of the City of Hope Comprehensive Cancer Center. Dr. Vaidehi received her Ph.D. in quantum chemistry from the Indian Institute of Technology in India, where she was honored with the Distinguished Alumni Award in 2016. Following her postdoctoral studies on protein dynamics simulation methods at University of Southern California, and at Caltech, she became the director of biomolecular simulations at the Materials and Process Simulation Center, Beckman Institute at Caltech. Dr. Vaidehi joined the Beckman Research Institute of the City of Hope in 2006 as a Professor and became chair of DCQM in 2018. She has advanced the use of computational methods to meet the challenges of designing therapeutics with lower off target effects. She is an internationally recognized biophysicist for her contributions in developing constrained molecular dynamics simulation methods with emphasis on application to G-protein coupled receptors and drug design." Dr. Nagarajan Vaidehi on the web City of Hope Google Scholar LinkedIn Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

A breakthrough in GPCR imaging reveals a full native pancreatic islet and advances how GLP-1R can be visualized in tissue using chemical probes. Home → Flash News → Lighting up a native pancreatic islet isn’t just a technical win it’s a shift in what GPCR imaging can reveal Lighting up a native pancreatic islet isn’t just a technical win — it’s a shift in what GPCR imaging can reveal Published on December 8, 2025 Category Our latest Dr. GPCR blog breaks down the moment Dr. Johannes Broichhagen and David Hodson realized their fluorescent peptide probe could visualize GLP-1R across an entire intact islet — not in an overexpression system, but in real tissue. This is the kind of advance that matters for anyone building tools, assays, or therapeutics around receptor biology: Higher fidelity GPCR imaging without antibody variability Surface-pool selectivity — the pharmacologically relevant population Compatibility with live cells, tissue, and deep-imaging setups A design logic that extends to other GPCRs Just as important: the collaboration model behind the science.Trust, interdisciplinary thinking, and a shared drive to build tools that actually work at the bench. If your team relies on receptor visualization — discovery, screening, translational work — this story has strategic takeaways you’ll want to steal. 🔗 Read the blog : https://www.ecosystem.drgpcr.com/post/when-the-islet-lit-up-advancing-gpcr-imaging-in-native-tissue #GPCR #DrGPCR #GPCRimaging #biotech #drugdiscovery Previous Next Recent Articles

Home → Flash News → Science isn't always about eureka moments—sometimes it's about steady progress. In our latest Dr. GPCR Podcast episode, Ian Chronis shares his top aha moments, from learning the hard way about gel electrophoresis to discovering the hidden complexities of GPCR signaling. ✅ https://buff.ly/FTB69y9 #GPCR #DrGPCR #SciencePodcast #Pharmacology Published on April 22, 2025 Category Dr. GPCR Podcast Science isn't always about eureka moments—sometimes it's about steady progress. In our latest Dr. GPCR Podcast episode, Ian Chronis shares his top aha moments, from learning the hard way about gel electrophoresis to discovering the hidden complexities of GPCR signaling. ✅ https://buff.ly/FTB69y9 #GPCR #DrGPCR #SciencePodcast #Pharmacology Previous Next Recent Articles

Home → Flash News → Did you know allosteric modulators can change the GPCR G protein subtype selectivity? Have a look at this study to dive deep into its molecular mechanism. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox. Published on December 12, 2024 Category GPCR Weekly News Did you know allosteric modulators can change the GPCR G protein subtype selectivity? Have a look at this study to dive deep into its molecular mechanism. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox. ➡ https:// www.ecosystem.drgpcr.com/gpcr-binders-drugs-and-more/design-of-allosteric-modulators-that-change-gpcr-g-protein-subtype-selectivity #gpcr #drgpcr Previous Next Recent Articles

A failed experiment led Dr. Jens Carlsson to his true calling—computational biochemistry. Discover how embracing failure turned frustration into a breakthrough career designing GPCR experiments before they happen. 🎧 Listen to his story on the Dr. GPCR Podcast. Home → Flash News → ep 175 with jens carlsson release picture Model. Predict. Discover. – Podcast Episode Release Published on October 22, 2025 Category Dr. GPCR Podcast What if a failed experiment became the best thing that ever happened to your career? Dr. Jens Carlsson started his journey aiming to be a biotech engineer. But during a summer internship in protein purification, he faced a harsh reality: lab work wasn’t his strength. The experiments didn’t work, the data didn’t flow, and it was frustrating. But in the quiet hours, he found himself drawn to the structures, to the models, to figuring out why things weren’t working. A professor noticed and called it out in a recommendation letter. That unexpected moment of clarity redirected his path. Today, Jens is a Professor of Computational Biochemistry at Uppsala University , where his lab uses structure-based modeling to predict GPCR-ligand interactions, before they’re ever tested in the lab. The mindset shift? Stop explaining experiments after they happen. Start designing them to happen. His journey is a powerful reminder that the right career often reveals itself through “failure.” Follow what lights you up. Notice where your mind naturally goes. And don’t ignore the signs, it might be your real path calling. 🎧 Listen to Jens’ full story on the Dr. GPCR Podcast : https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/model-predict-discover #DrGPCR #GPCR #CareerInScience #ComputationalBiology #DrugDiscovery #PhDLife Previous Next Recent Articles

A conversation with Prof. David Hodson on visualizing GLP-1 and GIP receptors in pancreatic islets and brain circuits to advance GPCR-targeted therapies for diabetes and obesity. << Back to podcast list Strategic Partner(s) Visualizing GLP-1 & GIP Receptors in Islets and Brain In this episode, Professor David Hodson discusses how GLP-1 and GIP receptors regulate metabolism across the pancreas and brain, and why visualizing receptor localization and signaling in real tissues is essential for advancing GPCR drug discovery . His team develops fluorescence-based and chemically engineered tools to study gpcr internalization and ligand engagement in intact islets and neuronal circuits — insights that inform next-generation functional assay development and translational therapeutic design. The conversation also highlights the role of interdisciplinary collaboration in accelerating innovation in diabetes and obesity research. Why this matters How receptor distribution in islets and brain circuits shapes incretin hormone drug effects Why visualization tools changed our understanding of GPCR signaling in metabolic tissues What collaborative chemistry enabled in designing receptor-targeted fluorescent ligands The moment when structural and imaging evidence clarified unexpected glucagon-derived peptide behavior How future metabolic therapies may evolve based on receptor cross-talk and tissue-specific engagement Who should listen Navigated complex datasets where interpretation depended on biological context Balanced innovation with the need for reproducible, well-controlled functional assays Worked across disciplines where chemistry, pharmacology, and physiology converge Questioned how drug action differs in real tissues vs. recombinant cell lines …this episode will resonate. About David Hodson Prof. David Hodson is the Robert Turner Professor of Diabetic Medicine at the University of Oxford , working within the Oxford Centre for Diabetes, Endocrinology and Metabolism. Originally trained as a Veterinary Surgeon , he completed postdoctoral research at the CNRS in Montpellier before establishing his independent laboratory at Imperial College London as a Diabetes UK RD Lawrence Fellow. He later served as Professor of Cellular Metabolism and Institute Deputy Director at the University of Birmingham. His group develops imaging and chemical biology tools to reveal how GLP-1 and GIP receptors operate within complex tissues, with direct relevance to type 2 diabetes and obesity therapy . David Hodson on the Web Radcliffe Department of Medicine Islet Biology Lab University of Birmingham Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Join the forefront of GPCR research at the Dr. GPCR Summit! Embracing innovation and technology, we connect global scientific communities. Experience talks spanning time zones, with options for live or pre-recorded presentations. Uncover groundbreaking insights in GPCR science together. Learn more. Meet Dr. GPCR Summit Partners - Click to Explore - Dr. GPCR Summit 2021 Welcome to the official page of the Dr. GPCR Virtual Summit 2021! << Live talk schedule >> << Pre-recorded talk list >> The program is complete! Don't miss a chance to listen to 25+ scientific talks, which will only be available for those who registered during the Summit. Get your All-Access ticket before they're gone by visiting Eventbrite today! Got your All-Access ticket already? Special shout out to our partners! Check your inbox this week, you'll be able to invite a friend or colleague to join the Summit for Free! Proceeds from the ticket sales will be used to provide the best three trainee talks with fantastic prizes, including a personalized autographed copy of Dr. Lefkowitz's biography. Present a pre-recorded talk and get free access to the entire Summit! Hurry, the deadline to submit your talk is Friday, September 10th, 2021, at midnight EST. If you're facing financial difficulties or are a trainee who would like to attend but can't submit a pre-recorded talk, reaches out to us now! The live talks will be held on Zoom, and everyone who registered will be able to ask their questions to the speakers all week on Microsoft Teams! You'll also be able to meet our partners on Microsoft Teams. Make sure you have a profile picture set for both Zoom and Microsoft Teams! Everyone is welcome to present their work (students, postdocs, PI's, biotech, pharma companies)! There are no posters! All pre-recorded talks will be available during the summit for free with registration. All live talks will have a $5 attendance fee/ talk You can get full access to all the talks for $100 For Speakers Step 1: Let us know that you'd like to present your work by filling out this short form here Step 2: Prepare your video abstract and your presentation (pre-recorded or live)* Step 3: Click here to send us your pre-recorded presentation or click here*** to submit the information to your live presentation before August 5th, 2021. ***All live talks are now scheduled Please provide us with your pre-recorded presentation by September 10th, 2021 *Note: Scroll down to find resources to help you prepare your video presentation, and don't hesitate to get in touch if you need help. Contact us at Hello@DrGPCR.com Some housekeeping items first We strongly suggest you carefully consider what type of information you share in your presentation. We will do our best to keep the Summit a closed event, but Dr.GPCR is not responsible for any loss of intellectual property. How will I access the talks during the Summit? You will receive an email from Eventbrite containing the relevant information before the summit. Be sure to register. How can I sponsor the 2021 Summit? Please visit our Sponsor Page to learn more about sponsorship opportunities to sponsor the Summit and the DrGPCR Ecosystem. For more information, please email us at Hello@DrGPCR.com In what form can I submit my abstract? Abstract submission can be in the form of classical text abstract or in the form of a short (max. 3 minutes) video. This is an excellent opportunity to be as creative as you want to be. We recommend writing a 200-300 word abstract, giving you enough information to provide a great video abstract in under 3 minutes. How will I present my talk? You can pre-record your talk. We recommend submitting pre-recorded talks. What does this mean? You send us the video of your full-length talk, and we will take care of the rest. Alternatively, you can provide us with the embed code to make your presentation available during the Summit. Pros: You can polish your recording to your satisfaction. Anyone can watch it from anywhere, even multiple times. Imagine binge-watching your favorite talk over and over whenever you want to during the Summit. Cons: It may take more time to record an excellent presentation, but nothing is impossible! Click here to submit your pre-recorded presentation. Can I present a live talk or event? How? In case you'd like to present a talk live, we'll help with it. Pros: It may take less time to prepare for the presentation Cons: You may make mistakes since it's a live event, and if you decide to keep your talk live only, participants can watch it only once. *Tip Become a DR. GPCR Member by creating your own personalized page. Read more about becoming a member here . If you need help preparing your pre-recorded video and video abstract check out these resources: How to record your talk in PowerPoint 365 How to record your talk using a previous PowerPoint version How to record your talk using Keynote on a Mac Do you have any questions? Email us at Hello@DrGPCR.com << Live talk schedule >> << Pre-recorded talk list >> Meet Dr. GPCR Summit Partners - Click to Explore - Tags Dr. GPCR Summit Dr. GPCR Summit 2021 Dr. GPCR Summit 2021 Pre-Recorded Talks Dr. GPCR Summit 2021 Live Talks

<< Back to podcast list Strategic Partner(s) Dr. Paul J. Gasser About Dr. Paul J. Gasser " I received my BS and MS in Zoology & Physiology at the University of Wyoming, where I studied signaling processes involved in light-induced regulation of melatonin synthesis in the rainbow trout pineal organ, a directly photosensitive endocrine organ. I received my PhD in Biology at Arizona State University, where I worked in the lab of Miles Orchinik, studying cellular mechanisms underlying non-genomic actions of corticosteroid hormones. My postdoctoral work, conducted at the University of Bristol, UK, in Christopher Lowry's lab, examined the role of organic cation transporter 3 (OCT3) in the regulation of monoamine signaling in the brain. I joined the faculty of Biomedical Sciences at Marquette in 2007. I teach undergraduate Biochemistry and a variety of graduate neuroscience courses. Research in my lab is currently focused on understanding the signal transduction pathways activated by beta-adrenergic receptors localized to the inner nuclear membrane and their role in the regulation of gene expression." Dr. Paul J. Gasser on the web Gasser Lab Marquette University Google Scholar ResearchGate LinkedIn Twitter Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Every receptor tells a story but GPCRs speak a language of organization. Dr. Michelle Halls unpacks how GPCR signaling isn’t just about ligand–receptor interaction. Home → Flash News → Every receptor tells a story Every receptor tells a story Published on November 11, 2025 Category Dr.GPCR Podcast Every receptor tells a story — but GPCRs speak a language of organization. Dr. Michelle Halls unpacks how GPCR signaling isn’t just about ligand–receptor interaction. It’s about where and how signaling happens — spatially confined microdomains, scaffolding proteins, and preassembled complexes that fine-tune the cell’s response. This level of organization defines specificity in signaling, and understanding it changes how we think about drug targeting and disease mechanisms. It’s a moment that reframes GPCR biology from static pathways to dynamic, organized systems — where complexity is the key to precision. 🎧 Watch this moment from our conversation, then listen to the full episode on leadership, luck, and GPCR signaling: 👉 https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/leadership-luck-and-gpcr-signaling #GPCR #DrGPCR Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) Dr. Graciela Pineyro About this episode: Dr. Graciela Pineyro is a professor of pharmacology at the department of pharmacology and physiology of the University of Montreal. She has done extensive work on the molecular pharmacology of opioid receptors and is currently focusing on the pharmacology of cannabinoids in the context of pain. We chatted about how the current pandemic has affected her personally and professionally. Dr. Graciela Pineyro on the web Dr. Graciela Pineyro on LinkedIn Dr. Graciela Pineyro - University of Montreal Dr. Graciela Pineyro - CHU Ste-Justine Research Centre Pineyro Lab Publications on Google Scholar Pineyro Lab on Pubmed Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → Ready to stand out in the GPCR world? Take advantage of a platform where you can network within your field! 🌍 Showcase your expertise by keeping your profile up-to-date on Dr. GPCR. Published on December 11, 2024 Category Dr. GPCR Profiles Ready to stand out in the GPCR world? Take advantage of a platform where you can network within your field! 🌍 Showcase your expertise by keeping your profile up-to-date on Dr. GPCR. ✳️Start today at https://www.ecosystem.drgpcr.com/account/my-account #gpcr #drgpcr Previous Next Recent Articles

Celtarys partners with Dr. GPCR to expand fluorescent ligand tools for GPCR drug discovery, connecting biotech startups and scientists worldwide. Home → Flash News → ⚠️ Registration Deadline today! This is your last chance to register for Principles of Pharmacology II - Advanced Methods for the Optimization of Candidate Selection with Dr. Terry Kenakin. Learn more about new ligands and new GPCR behaviors that produce unique drug profiles. Published on October 15, 2024 Category Dr. GPCR Courses ⚠️ Registration Deadline today! This is your last chance to register for Principles of Pharmacology II - Advanced Methods for the Optimization of Candidate Selection with Dr. Terry Kenakin. Learn more about new ligands and new GPCR behaviors that produce unique drug profiles. ✳️ Last chance!!! https://www.ecosystem.drgpcr.com/advanced-methods-for-the-optimization-of-candidate-selection #gpcr #drgpcr Previous Next Recent Articles

Home → Flash News → “Research is all about knowing when to walk and when to run.” –Ben Clements In Ep. 166 of the Dr.GPCR Podcast, hear how a postdoc is reshaping the conversation on opioid use, imposter syndrome, and the power of collaborative science. Why early-career voices are critical in GPCR drug discovery —and how lab culture makes all the difference. 🎧 Watch here: https://buff.ly/Kr3qKud #GPCRresearch #DrGPCR #GPCRpodcast #OpioidPharmacology #DrugDiscovery Published on May 20, 2025 Category Dr. GPCR Podcast “Research is all about knowing when to walk and when to run.” –Ben Clements In Ep. 166 of the Dr.GPCR Podcast, hear how a postdoc is reshaping the conversation on opioid use, imposter syndrome, and the power of collaborative science. Why early-career voices are critical in GPCR drug discovery —and how lab culture makes all the difference. 🎧 Watch here: https://buff.ly/Kr3qKud #GPCRresearch #DrGPCR #GPCRpodcast #OpioidPharmacology #DrugDiscovery Previous Next Recent Articles

Home → Flash News → Did you know that GPR180 helps regulate lipid metabolism and may play a role in preventing obesity? recent study shows that overexpression of GPR180 in adipose tissue improves lipid metabolism and protects against HFD-induced obesity, while its knockout worsens lipid accumulation. This finding highlights GPR180 as a potential therapeutic target for metabolic disorders! Catch up on this exciting research in the Ecosystem today! 🏆📖 You’ll need to register, but don’t worry—it’s free! ➡️https://www.ecosystem.drgpcr.com/gpcrs-in-cardiology-endocrinology-and-taste/gpr180-reduces-adiposity-by-inhibiting-lipogenesis-and-fatty-acid-uptake-in-adipocytes #gpcr #drgpcr #metabolism #obesity Published on March 3, 2025 Category GPCR Weekly News Did you know that GPR180 helps regulate lipid metabolism and may play a role in preventing obesity? recent study shows that overexpression of GPR180 in adipose tissue improves lipid metabolism and protects against HFD-induced obesity , while its knockout worsens lipid accumulation . This finding highlights GPR180 as a potential therapeutic target for metabolic disorders! Catch up on this exciting research in the Ecosystem today! 🏆📖 You’ll need to register, but don’t worry—it’s free ! ➡️ https:// www.ecosystem.drgpcr.com/gpcrs-in-cardiology-endocrinology-and-taste/gpr180-reduces-adiposity-by-inhibiting-lipogenesis-and-fatty-acid-uptake-in-adipocytes #gpcr #drgpcr #metabolism #obesity Previous Next Recent Articles Early Stage Biotech Hiring: What Really Holds a Team Together When the Science Starts to Drift 👉 In early-stage biotech , uncertainty is not an exception. It is the environment. The science evolves, assumptions break, and timelines shift quietly rather than dramatically. Most founders are prepared for this on a technical level. What they are less prepared for is how much this uncertainty tests the team. Early hiring decisions are usually made around skills, experience, and domain expertise. That feels logical. 👉 Complex biology seems to demand strong credentials. Bu Attila Foris 5 days ago The One Reason Why Biotech Startups Fail More Often Than They Should Biotech startups rarely fail all at once. They fail while everyone is still working hard. Experiments continue. Meetings happen. Progress is reported. Yet alignment fades and decisions lose clarity. This is not a motivation problem. It is structural. When complexity grows faster than strategy, biotech companies drift. Survival depends less on science and more on whether clarity scales with complexity. Attila Foris Jan 7 Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris Dec 31, 2025 The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025

Join us in strengthening the global GPCR community. Your tax-deductible donation supports education, collaboration, and innovation. Dr GPCR is a 501(c)(3) non-profit. Support the GPCR Community — Empower the Next Generation of Discovery Your donation helps us serve the global GPCR community better — by upgrading the Dr GPCR University, creating more learning opportunities, and connecting scientists, students, and biotech innovators. - Secure donation through Wix - Dr. GPCR is a registered 501(c)(3) non-profit organization. 👉 Donate Now Why Donate? Every contribution helps us bridge the gap between academia and biotech — transforming knowledge into real-world impact more quickly. Your donation directly supports: Dr GPCR University : expanding and modernizing our educational programs to make cutting-edge GPCR knowledge accessible to everyone Dr GPCR Retreat: offering free or affordable gatherings that foster collaboration and mentorship across disciplines Happy Hours: informal, community-driven networking events that connect scientists, founders, and innovators in a relaxed setting Job Board: helping researchers and biotech companies find the right opportunities to grow together Community Infrastructure: maintaining the tools and platforms that keep the Dr GPCR Ecosystem open and thriving *Together , we’re creating a global home for everyone passionate about GPCR research, collaboration, and discovery. How Your Gift Helps? Every donation fuels the mission to make GPCR education and collaboration more accessible to everyone in the community. - $25+ 👉 Keeps Dr GPCR Happy Hours and community events free or affordable for participants around the world - $250+ 👉 Expands Dr GPCR University with new lessons, updated materials, and interactive learning modules - $5,000+ 👉 Powers new GPCR educational initiatives — including scholarships, retreats, and mentorship opportunities - $20,000+ 👉 Become a Strategic Partner — recognized across Dr GPCR channels for enabling global collaboration and impact Every contribution, big or small, helps the GPCR community learn, connect, and innovate together. 🎓 Elevate the University — Donate Today ❤️ Donor Recognition We believe generosity deserves visibility. Every donor receives a personal thank-you email and receipt Selected donors are thanked publicly in podcast intros, videos, or events Donations above $20 K are acknowledged as Strategic Partners , featured on our website and community pages Donate Frequency One time One time Monthly Monthly Yearly Yearly Amount $25 $25 $250 $250 $1,000 $1,000 $5,000 $5,000 Other Other 0/300 Comment (optional) Donate $25 FAQ Is my donation tax-deductible? Yes. Dr GPCR is a registered 501(c)(3) non-profit organization. Contributions are tax-deductible to the extent permitted by law. Can I make a donation on behalf of a company? Yes — Use the “Comment” section to add the company name in the donation form, and we’ll provide an invoice/receipt. Can I become a monthly supporter? Absolutely. Monthly donations sustain long-term programs and can be changed at any time. Can I be recognized publicly? Yes — we love thanking our donors through the Podcast, YouTube, and Summit platforms. Help us close the gap between academia and biotech. Together, we can accelerate GPCR discoveries and develop more effective drugs for everyone. 👉 Donate Now to Support the Dr GPCR Ecosystem

Sokhom Pin shares how he built a biotech career around GPCRs, designed a custom PhD path, and led teams through empowerment and purpose. << Back to podcast list Strategic Partner(s) GPCR Pharmacology, Career Twists & Serendipity with Sokhom Pin 1. From the Bench to the Boardroom Sokhom Pin’s story begins not with prestige or privilege but with grit and commitment. From his early work as a technician at Johns Hopkins Hospital to leading biology at Servo Therapeutics, Sokhom’s journey is rooted in practicality and purpose. He shares: "All my industry experience has been GPCR-focused." Starting at DuPont, then BMS, Novartis, and eventually founding in vitro pharmacology departments, Sokhom always stayed anchored to G protein-coupled receptors (GPCRs). 2. Family First, Always The decision to shift from academia to industry wasn’t driven by disillusionment—it was about responsibility. “I had two kids and realized I just couldn’t support a family on a technician’s salary.” This pragmatic decision led him to high-throughput screening at DuPont, proving that scientific ambition doesn’t have to mean sacrificing personal commitments. 3. Falling in Love with GPCRs GPCR pharmacology captured his scientific curiosity. Sokhom recalls how binding assays at BMS introduced him to the depth and complexity of receptor pharmacology: “It’s not just about IC50s. There’s allosterism, receptor desensitization… it opened a whole new world.” This moment became pivotal—transforming technical proficiency into passion. 4. Designing a Non-Traditional PhD While working full-time, Sokhom architected a one-of-a-kind PhD program between BMS and UConn. “I had to find a way. I wanted a PhD, but I couldn’t quit my job.” Through strategic coordination, he executed a PhD entirely in the industry setting—efficient, targeted, and rooted in real-world projects like CGRP receptor antagonists. 5. From Scientist to Leader At Alkermes, Sokhom took his first leadership role and finally experienced the power of empowerment . “That’s the moment that changed my entire career. I was trusted to build a team from scratch.” He focused on culture—ensuring passion and purpose drove performance. 6. The Power of the Right Culture Whether it was Alkermes or Cerevel, Sokhom emphasized that team culture trumps individual genius . “It doesn’t matter how brilliant someone is—if they’re toxic, I don’t want them on the team.” He built what others called the “happiest team at Alkermes,” showing that joy and scientific rigor aren’t mutually exclusive. 7. Network or Miss Out One powerful shift came when Sokhom leaned into networking—despite being an introvert. “I changed from being an extreme introvert to someone who thrives on connection.” His story underscores how something as simple as forwarding a resume or reaching out for coffee can change careers. 8. The Lifecycle of GPCR Popularity Sokhom has witnessed the waves of scientific fashion: “There was a time GPCRs were hot, then ignored. Now they’re back.” His unwavering dedication through these cycles became an asset—many others shifted focus, leaving a smaller, highly skilled group of GPCR specialists. 9. Lessons from Molecules and Mentors He draws inspiration from scientific complexity and colleagues like Arthur Christopoulos and Terry Kenakin. “What fascinates me is how the same molecule behaves differently depending on one amino acid.” He blends classical receptor pharmacology with biosensor technology, always adapting to new tools and insights. 10. Don’t Let Weakness Define You The episode ends with a deeply human reflection: “Don’t let your weakness define your life. Overcome it. I used to sweat thinking about presentations. Now I love them.” Whether it’s networking, leadership, or technical mastery, Sokhom’s message is clear: keep evolving, and don’t settle. ________ Key Takeaway Sokhom Pin's journey is a masterclass in scientific persistence , non-traditional success , and values-driven leadership . For any scientist navigating career uncertainty—his story is both roadmap and inspiration. Keyword Cloud GPCR research community , Dr. GPCR ecosystem , GPCR scientist network , GPCR drug discovery , GPCR training program , GPCR online course , G protein-coupled receptors , GPCR podcast , GPCR webinar series , GPCR data platform Summary created by AI ________ About Sokhom Pin Sokhom Pin is a receptor pharmacologist with over 20 years of drug discovery research in the pharmaceutical industry, where he works mainly on GPCRs as therapeutic targets. He is passionate about mechanistic profiling of therapeutic molecules as well as drug discovery in general. Outside of science Sokhom enjoys outdoor activities such as hiking, boating, fishing, and biking. Sokhom Pin on the web LinkedIn Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>